BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Some examples include Osimertinib—which irreversibly binds the EGFR kinase and, therefore, blocks signaling pathways downstream— imatinib—which targets the BCR-ABL fusion protein in chronic myelogenous leukemia— and ibrutinib—which targets the Bruton’s tyrosine kinase, a key enzyme in the BCR pathway.